最終更新日:2022/12/24
More recently, other biological drugs, such as ustekinumab, ixekizumab, tofacitinib, secukinumab and briakinumab, have targeted immunological mediators of the disease.
編集履歴(0)
More recently, other biological drugs, such as ustekinumab, ixekizumab, tofacitinib, secukinumab and briakinumab, have targeted immunological mediators of the disease.